Want to see SHTDY full AI Analyst Report?
Sinopharm Group Co (SHTDY) AI Stock Analysis
Sinopharm Group Co
(Other OTC:SHTDY)
Moderate financial performance weighs on the score due to revenue declines and high debt, offset by attractive valuation and neutral technicals; low beta adds stability in the Medical - Distribution industry.
Sinopharm Group Co (SHTDY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.43B
- Dividend Yield
- 4.87%
- Average Volume (3M)
- 142.96K
- Price to Earnings (P/E)
- 6.1
- Beta (1Y)
- 0.08
- Revenue Growth
- 2.49%
- EPS Growth
- 7.42%
- Country
- US
- Employees
- 94,910
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharma...
How the Company Makes Money
Sinopharm Group generally makes money through: (1) Pharmaceutical and healthcare product distribution: The core revenue stream is selling pharmaceuticals and other healthcare products (including medicines, medical devices, and consumables) to institu...
Sinopharm Group Co Financial Statement Overview
Summary
Moderate financial health with steady operations and growing equity, but concerns over declining revenue, thin margins, high debt, and weakening cash flows result in an average score from income (65), balance sheet (58), and cash flow (60).
Income Statement
65PositiveBalance Sheet
58NeutralCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 563.46B | 559.50B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 39.34B | 40.09B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 21.29B | 20.50B | 22.55B | 26.90B | 26.25B | 24.68B |
| Net Income | 6.99B | 6.96B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | ||||||
| Total Assets | 404.57B | 390.61B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 41.90B | 61.60B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 81.32B | 108.65B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 268.18B | 256.36B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 85.22B | 84.01B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | ||||||
| Free Cash Flow | 20.67B | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 22.20B | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -552.41M | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -27.38B | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Positive. The current price of 10.40 is above the 20-day moving average (MA) of 9.84, above the 50-day MA of 9.82, and below the 200-day MA of 11.24, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 61.92 is Neutral, neither overbought nor oversold. The STOCH value of 70.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SHTDY.
Sinopharm Group Co Peers Comparison
Overall Rating
MCK74Outperform
COR71Outperform
CAH68Neutral- SHTDY68Neutral
HSIC55Neutral
YI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MCK | 74Outperform | $115.96B | 26.50 | -194.39% | 0.34% | 8.84% | 48.98% |
| COR | 71Outperform | $63.13B | 24.47 | 106.43% | 0.73% | 5.09% | 38.10% |
| CAH | 68Neutral | $58.00B | 34.45 | -59.73% | 0.82% | 14.23% | 12.28% |
| SHTDY | 68Neutral | $6.44B | 6.09 | 8.33% | 4.87% | 2.49% | 7.42% |
| HSIC | 55Neutral | $9.46B | 24.53 | 12.37% | ― | 6.49% | 10.41% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| YI | 40Underperform | $25.04M | -1.59 | 23.64% | ― | -23.90% | -45.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SHTDY | Sinopharm Group Co., Ltd. Unsponsored ADR Class H | 10.32 | -1.61 | -13.50% | |
| COR | Cencora, Inc. | 330.84 | -7.51 | -2.22% | |
| CAH | Cardinal Health | 250.48 | 62.04 | 32.92% | |
| HSIC | Henry Schein | 84.88 | 20.24 | 31.31% | |
| MCK | McKesson Corporation | 994.58 | 177.51 | 21.72% | |
| YI | 111, Inc. | 2.85 | -1.51 | -34.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026